C12N 2795/18151
Methods of production or purification of viral material
C12N2795/18151 (Methods of production or purification of viral material) appears on 4 US grants and 12 published applications in this corpus.
Search patents in C12N- Granted patents
- 4
- Published applications
- 12
- Assignees
- 10
- Inventors
- 25
- Latest grant
- 21 Sep 2021
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 2 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 2 |
| 2017 | 1 | 0 |
| 2018 | 1 | 2 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 1 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Subgroups
Granted patents
Recent patents
- Retroviral particle comprising at least two encapsidated nonviral RNAs21 Sep 2021US 11,124,775 B2Flash Therapeutics
- Compositions and methods for inhibiting gene expressions3 Apr 2018US 9,932,563 B2Georgia Tech Research Corporation
- Scalable process for protein purification23 May 2017US 9,657,065 B2Kuros Biosciences AG
- Scalable process for protein purification15 Feb 2011US 7,888,098 B2Cytos Biotechnology AG
- Methods and compositions for determining the antigen specificity of t cells13 Mar 2025US 2025/0084479 A1The Broad Institute, Inc.
- Retroviral particle comprising at least two encapsidated nonviral rnas30 Sep 2021US 2021/0301265 A1Flash Therapeutics
- Retroviral particle comprising at least two encapsidated nonviral rnas17 May 2018US 2018/0135025 A1Vectalys SAS
- Construction and application of one innovative expression vector for virus-like particles10 May 2018US 2018/0127837 A1Chinese Academy of Inspection and Quarantine
- Compositions and methods using capsids resistant to hydrolases21 Jul 2016US 2016/0208221 A1Apse, Inc.
Most cited
By later US patents